Objective: The link between excess intra-abdominal adiposity (IAA) and metabolic complications leading to type 2 diabetes and cardiovascular disease is well recognized. Blockade of endocannabinoid action at cannabinoid CB 1 receptors was shown to reduce these complications. Here, we investigated the relationship between IAA, circulating endocannabinoid levels and markers of cardiometabolic risk in male obese subjects. Design, subjects and measurements: Fasting plasma levels of the endocannabinoids, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), were measured by liquid chromatography-mass spectrometry in a study sample of 62 untreated asymptomatic men with body mass index (BMI) from 18.7 to 35.2 kg/m 2 . Results: Plasma 2-AG, but not AEA, levels correlated positively with BMI, waist girth, IAA measured by computed tomography, and fasting plasma triglyceride and insulin levels, and negatively with high-density lipoprotein cholesterol and adiponectin levels. Obese men with similar BMI values (X30 kg/m 2 ) but who markedly differed in their amount of IAA (o vsX130 cm 2 , n ¼ 17) exhibited higher 2-AG levels in the presence of high IAA. No difference in 2-AG concentrations was observed between obese men with low levels of IAA vs nonobese controls. Conclusions: These results provide evidence for a relationship in men between a key endocannabinoid, 2-AG, and cardiometabolic risk factors, including IAA.
Introduction
The link between abdominal obesity (resulting from excess intra-abdominal adiposity (IAA)) and the development of many metabolic complications leading to type 2 diabetes and cardiovascular disease is now well recognized. 1 Although lifestyle modification is the cornerstone of management of patients with excess IAA, new therapeutic targets must be identified to optimally manage the cardiometabolic profile of high-risk abdominally obese patients. Among these relevant targets, the endocannabinoid system, consisting of two cannabinoid receptors (CB 1 and CB 2 ) and endogenous ligands, anandamide (AEA), 2-arachidonoylglycerol (2-AG), 2 has been shown to play a major role in the regulation of energy balance and body composition. 2, 3 Furthermore, two cannabinoid receptor-inactive and biosynthetically related congeners of AEA, oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), have been suggested to activate the peroxisome proliferator-activated receptor-a (PPAR-a) and to control hyperlipidemia. 4 Recently, blockade of the cannabinoid CB 1 receptor has been shown to reduce body weight and waist circumference, to improve plasma glucose-insulin homeostasis and to increase high density lipoprotein (HDL) cholesterol levels and adiponectin concentrations in obese patients. 3, 5 In addition, the recent finding of a missense polymorphism in an endocannabinoid degrading enzyme, the fatty acid amide hydrolase (FAAH), associated with overweight and obesity supports the notion that the endocannabinoid system is upregulated in obesity. 2, 6 On the basis of this background, the objective of the present study was to investigate the associations between the levels of AEA, 2-AG, OEA and PEA and body fat distribution assessed by computed tomography (intra-abdominal and subcutaneous adipose tissue (AT)) in a sample of nondiabetic men covering a wide range of adiposity values.
Methods

Subjects
The study sample included 62 men (mean age7s.d.: 42.177.8 years) who were recruited from the Québec City metropolitan area by solicitation through the media. All subjects were healthy, nonsmoking volunteers, and were not under treatment for coronary heart disease, diabetes, dyslipidemias or endocrine disorders. All participants gave their written consent to participate in the study, which was approved by the Medical Ethics Committee of Laval University.
Anthropometric measurements and computed tomography
Height, body weight 7 and waist circumference 8 were measured following standardized procedures. Body density was measured by the hydrostatic weighing technique. 9 The mean of six measurements was used to calculate percent body fat from body density using the equation of Siri. 10 Fat mass was obtained by multiplying body weight by percent body fat. Measurement of abdominal AT areas was performed by computed tomography with a Siemens Somatom DHR scanner (Erlanger, Germany) as described previously.
11
Plasma lipoprotein-lipid variables Blood samples were collected in the morning from an antecubital vein into vacutainer tubes containing EDTA (ethylenediaminetetraacetic acid) (Miles Pharmaceuticals, Rexdale, Ontario, Canada) after a 12-h overnight fast for the measurement of plasma lipid and lipoprotein levels. Cholesterol and triglyceride levels were determined in plasma and lipoprotein fractions on Technicon RA-500 (Bayer), and enzymatic reagents were obtained from Randox. Plasma very low-density lipoproteins (density 41.006 g/ml) were isolated by ultracentrifugation. 12 The HDL fraction was obtained after precipitation of low-density lipoprotein (LDL) in the infranatant (density 41.006 g/ml) with heparin and MnCl 2 . 13 The cholesterol and triglyceride concentrations of the infranatant were measured before and after the precipitation step.
Oral glucose tolerance test A 75 g oral glucose tolerance test (OGTT) was performed in the morning after an overnight fast. Blood samples were collected in EDTA-containing tubes through a venous catheter placed in an antecubital vein at À15, 0, 15, 30, 45, 60, 90, 120, 150 and 180 min for the determination of plasma glucose and insulin concentrations. Plasma glucose was measured enzymatically, 14 whereas plasma insulin was measured by radioimmunoassay with polyethylene glycol separation. 15 The total glucose and insulin areas under the curve areas under the curve (AUC) during the OGTT were determined with the trapezoid method.
Determination of adiponectin concentrations
Fasting plasma adiponectin concentrations were determined by an enzyme-linked immunosorbent assay (B-Bridge International Inc., San Jose, CA, USA), on whole plasma kept at À801C before use. The intra-assay and interassay coefficients of variation are 3.3 and 7.4%, respectively.
Measurement of plasma endocannabinoid levels
The extraction, purification and quantification of AEA, 2-AG, OEA and PEA in serum was performed as described previously. 16 After addition of 100 pmol of the respective deuterated internal standards in the serum, repeated (three times) lipid extraction with chloroform:methanol (2:1 by vol), and pre-purification on silica mini-columns eluted with chloroform:methanol (9:1 by vol), chromatographic fractions containing the compounds were subjected to isotopedilution liquid chromatography-atmospheric pressure chemical ionization-mass spectrometric analysis as described previously. 16 The amounts of the compounds were calculated by isotope dilution and expressed as pmol/ml of blood. ) had been previously reported to be associated with a significant deterioration of metabolic variables predictive of type 2 diabetes and cardiovascular disease. 17 A one-way analysis of variance (ANOVA) was used to compare the group of lean men with the two subgroups of obese subjects. Differences between groups were tested using ANOVA followed by Duncan's multiple range tests. All statistical analyses were performed with the SAS statistical system (SAS Institute, Cary, NC, USA). In all analyses, a P-value of less than 0.05 was considered statistically significant.
Statistical analyses
Results
The anthropometric and metabolic characteristics of the 62 men in the study presented in Table 1 shows that subjects 2-Arachidonoylglycerol in abdominally obese males M Côté et al covered a wide range of BMI values and body fat distribution indices. Correlation analyses revealed significant relationships between 2-AG levels and many variables of adiposity as well as cardiometabolic risk parameters (Table 2) . Plasma 2-AG levels were positively correlated with BMI (r ¼ 0.30, Po0.01), waist girth (r ¼ 0.30, Po0.02), IAA (r ¼ 0.43, Po0.0004), triglyceride levels (r ¼ 0.37, Po0.003), fasting insulin levels (r ¼ 0.37, Po0.003) and negatively correlated with HDL cholesterol levels (r ¼ À0.25, Po0.04) and adiponectin levels (r ¼ À0.28, Po0.02). In contrast, no relationships were found between AEA with BMI and waist circumference. However, a negative correlation was observed between AEA levels and IAA (r ¼ À0.37, Po0.003). The two other endocannabinoids investigated, OEA and PEA, showed no association with anthropometric and metabolic parameters (data not shown). Figure 1 presents BMI and IAA values according to tertiles of 2-AG ( Figure 1a ) and AEA levels ( Figure 1b ). Despite the fact that no difference was observed in BMI values across tertiles, men in the upper tertile of 2-AG concentrations were characterized by the highest IAA levels, whereas subjects in the top tertile of AEA levels were characterized by the lowest accumulation of IAA.
In addition, Figure 2 shows that increased 2-AG levels (top tertile) were associated with a more deteriorated metabolic risk profile as compared to subjects with reduced 2-AG levels (lowest tertile). (n ¼ 28). Comparison of these two subgroups of obese patients differing in their IAA accumulation revealed a marked increase of plasma 2-AG levels in obese men with excess IAA. Whereas no difference was observed between obese men with low IAA (0.8670.53 pmol/ml) and nonobese controls (0.9070.36 pmol/ml), a marked increase in 2-AG levels was noted in obese men with excess IAA (1.3770.71 pmol/ml). This analysis also revealed that obese men with excess IAA were characterized by the lowest AEA levels (2.2470.28 pmol/ml) as compared to obese men with low IAA (3.2770.65 pmol/ml) or nonobese men (2.9870.91 pmol/ml). Furthermore, no difference was observed between the three subgroups with regard to OEA and PEA levels (data not shown).
Finally, oral glucose tolerance was compared across tertiles of plasma 2-AG levels (Figure 3b ). Subjects in the top 2-AG tertile were characterized by a significantly greater glycemic response to the 75 g oral glucose load than men in the lowest tertile of plasma 2-AG levels (Po0.02).
Discussion
We have reported here that, among the endogenous cannabinoids and related compounds studied, 2-AG was the most related to adiposity indices, particularly with IAA. For instance, the levels of 2-AG, but not AEA, positively correlated with BMI, waist circumference and IAA, whereas no relationship was observed with subcutaneous AT. To further investigate the association between 2-AG and IAA, ) being characterized by a significant increase in 2-AG levels compared to obese men with low levels of IAA (o130 cm 2 ). These results are concordant with previous results using waist circumference as an anthropometric index of abdominal adiposity revealing an independent association of waist circumference to 2-AG levels. 18 Furthermore, these data agree with our observations indicating elevated 2-AG, but not AEA, PEA or OEA concentrations, in the visceral but not subcutaneous AT of obese patients. 19 In the present study, plasma 2-AG levels were also significantly associated with some key cardiometabolic risk markers such as high triglyceride and insulin levels, and low HDL cholesterol and adiponectin levels. In this regard, the RIOLipids trial conducted on high-risk dyslipidemic patients showed that CB 1 receptor blockade by rimonabant could induce a substantial increase in HDL cholesterol and adiponectin levels, which was not entirely dependent on weight loss. 5 Thus, bearing in mind that 2-AG has a stronger impact on CB 1 receptor functional activity than AEA (see below), our observations are in line with (and in fact might underlie part of) the findings of clinical trials showing that blockade of CB 1 receptors leads to increased adiponectin and HDL cholesterol levels as well as increased insulin sensitivity. 3, 5, 20 An intriguing finding of our study was that AEA levels seemed inversely related to IAA accumulation. In contrast to 2-AG levels, no relationships were observed between AEA with BMI and waist circumference, but a negative correlation was observed with IAA. Moreover, AEA levels correlated negatively with fasting insulin levels but with no other risk factor, thus suggesting that the correlations that we have observed here between 2-AG levels and other risk factors are not merely the consequence of correlations between the latter and IAA. Further analysis revealed that obese men with excess IAA were characterized by the lowest AEA levels as compared to obese men with low IAA accumulation or nonobese men. Furthermore, this analysis indicated that the highest levels of AEA were found in normal weight rather than in viscerally obese men. At first glance, these results seem in contrast with previous results by Engeli et al., 18 who reported increased circulating levels of AEA in obese postmenopausal women compared to lean women. The difference between the two studies could be attributed to the fact that we have studied only male subjects. Furthermore, Engeli et al. did not study the correlation with IAA, and it is possible 
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that the subjects used in their study, being women, were not predominantly viscerally obese. Obviously, additional studies will be required to better understand this potential gender difference in AEA levels as well as the relationship between AEA levels and IAA. It must be remembered, however, that 2-AG, rather than AEA, is believed by many as the only truly selective and most efficacious endocannabinoid, 21 that AEA has also been reported to bind to several other molecular targets, 22 and that it is not unusual to find that these two endocannabinoids undergo differential or opposing changes and potentially play different roles, during physiological or pathological conditions, including obesity. 19, 23, 24 In particular, and possibly relevant to our present findings, AEA, but not 2-AG, was recently reported to activate mouse adipocyte PPAR-g directly and in a way independent of CB 1 receptors. 25 AEA levels peak before adipocyte maturation and PPAR-g full expression in mouse adipocytes, and decrease significantly in hypertrophic adipocytes, where, instead, 2-AG levels and CB 1 expression remain elevated, thus mimicking the situation in the epididymal fat of mice with diet-induced obesity. 19 These previous observations indicate that, particularly at the level of the white AT, 2-AG and AEA might play different functional roles, the activity and levels only of the former compound appearing to be tightly associated with those of CB 1 receptors. In a previous study carried out by us in 10 patients (four men, six women) with type 2 diabetes and similar BMI (33.5 kg/m 2 ), but with much higher fasting glucose levels (10.28 mmol/l) than those of the obese male patients examined here, the blood 2-AG levels were reported to be higher than those found here in viscerally obese individuals. 19 Such difference might be due to the fact that chronic hyperglycemia has been shown to significantly upregulate the levels of 2-AG independently of other cardiometabolic risk factors, as shown in RIN-m5F insulinoma cells. 19 On the other hand, we do not have as good an explanation as to why the levels of AEA in lean patients from Matias et al's 19 study (B1.8 pmol/ml) were lower than those found in lean subjects in the present study (B3.41 pmol/ml), whereas 2-AG levels (B0.75 pmol/ml) were similar in the lean subjects from both studies. Perhaps age (B62 years in the previous study vs B42 years in the present study) might be the reason for this discrepancy, as in laboratory animals it was found that AEA and N-acylethanolamine, but not 2-AG, levels decrease with old age, at least in some brain areas. 26, 27 Accordingly, higher blood AEA, but not 2-AG, levels were found in the previous study in the blood of B32-vs Figure 2 Relationships between tertiles of plasma 2-AG levels vs selected cardiometabolic risk variables. 1,2: significantly different from the corresponding tertile (Po0.05).
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M Côté et al B62-year-old healthy volunteers (B2.6 vs B1.8 pmol/ml), despite the fact that the latter exhibited higher BMI (28.6 vs 21.7 kg/m 2 ). 19 However, no systematic study has been carried out in human subjects to evaluate specifically the effect of age on plasma endocannabinoid levels. Another finding of the present study is that the blood levels of OEA and PEA, two AEA congeners that have been proposed as endogenous ligands of PPAR-a 4,28 do not change in obese men, nor are they correlated with IAA or any of the other cardiometabolic risk factors analyzed here. This finding might suggest that these two compounds do not play a major role in these risk factors or in visceral obesity, and validates the methods used in the present study by indicating that the changes observed here are selective for endogenous ligands of cannabinoid receptors. A clear limitation of the present study is its largely descriptive character and the lack of conclusive evidence for a clear cause-effect relationship between elevated plasma 2-AG levels and cardiometabolic risk factors, although several studies in animals do suggest a causative role for peripheral CB 1 receptors in obesity and AT and liver dysfunction 2, 19, 24 (see also below). Clearly, to circumvent this limitation, further study-intervention trials to be targeted, for example, at the reduction of IAA are necessary to support the hypothesis that this cardiometabolic risk factor positively impacts on plasma 2-AG levels. Furthermore, studies need to be designed in both humans and animals to assess whether elevated 2-AG levels are one of the causes or, instead, a consequence of high IAA. Another unavoidable limitation of this study, as well as of previous analogous studies, 18 is represented by the fact that plasma levels of endocannabinoids, that is of compounds supposed to act locally as paracrine/autocrine mediators, were measured. Clearly, bearing in mind the high number of samples necessary to carry out correlative studies, and the limited number and potential artifactual nature of measurements in frozen bioptic or postmortem tissues, blood sampling was the only possible way to carry out the present study in several patients. Nevertheless, we do believe that the levels of endocannabinoids measured in the blood, rather than possessing a biological significance per se, are to a great extent representative of a situation occurring in the AT and possibly other peripheral organs in obese individuals. This is particularly true if one takes into consideration: (i) the above-mentioned previous data obtained in a limited number of nonobese and obese patients, and showing again a Btwo-fold elevation of 2-AG, but not AEA, levels in visceral but not subcutaneous fat; 19 (ii) the finding of a correlation between a potential genetic malfunctioning of endocannabinoid degradation and human overweight/obesity; 6 and (iii) data indicating that 2-AG levels are significantly elevated in the epididymal fat of mice with diet-induced obesity. 
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During the revision process of the present article, Blüher et al. 29 reported results similar to ours from a study carried out in 60 normoweight and obese patients with or without high IAA. These authors showed that the blood levels of 2-AG, but not AEA, correlate positively with BMI, IAA and percent body fat in both men and women. Positive correlations of circulating 2-AG levels with measures of glucose intolerance as well as serum triglycerides and free fatty acids, and a negative correlation with HDL cholesterol were also observed. However, the authors did not find any negative correlation between 2-AG and adiponectin levels, nor between AEA levels and IAA (although a trend was observed in the latter case). These differences might be due to the fact that: (i) the statistical power of Blüher et al.'s 29 study was lower than ours (with blood analyzed in 30 vs 62 male patients, respectively); (ii) the patients participating in our study, unlike those of Blüher et al.'s study, were not under medication; and (iii) the two cohorts of patients exhibited also significantly different ranges in several anthropometric parameters, including visceral fat area subcutaneous fat area, waist circumference, BMI and age. An B7.5-fold difference in average blood 2-AG levels was also noticeable between the two studies. This, apart from the above anthropometric differences, might be due to the different procedures used for the sampling and extraction of blood and for the measurement of endocannabinoids, that is factors that can sensibly affect the absolute values of endocannabinoid levels detected in tissues and blood. 30 In conclusion, we have reported that plasma 2-AG levels are markedly increased with IAA accumulation. Among the endocannabinoids and related compounds studied, 2-AG was the only one positively associated with IAA. Plasma 2-AG levels are therefore more closely related to IAA than total adiposity. These results are consistent with the previously suggested role of the endocannabinoid system in the regulation of body fat distribution. If the elevated levels of 2-AG found here to be associated with IAA and other cardiometabolic risk factors reflect a similar upregulation at the level of peripheral tissues, and result in a higher activity of CB 1 receptors despite the lower levels of AEA, they might, through mechanisms that have been well described in preclinical studies, 19, 24 play a causative role in excessive free fatty acid and triglyceride synthesis in the liver and enhanced lipogenesis and reduced adiponectin release in the white AT, which are hallmarks of IAA. This would help explaining why in obese patients CB 1 blockade reduces BMI, increases HDL cholesterol, reduces triglycerides, alters LDL particle size and improves glucose tolerance and insulin sensitivity, that is some of the metabolic risk factors found here to be correlated with plasma 2-AG levels.
